A Phase 2 interventional study of Alisertib in Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Burkitt's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-27.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.
Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 383rd largest by enrollment of the 963 interventional ones that give a count, is one of 31 that started in 2009, is one of 380 in phase 2, and was the 481st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Nathan Denlinger · Sites in United States
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 542 · Phase 2 537 · Phase 3 82 · Phase 4 2
First in 1988; this study’s year is marked. 31 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 37 across the 963 interventional studies, 84 across the 66 observational. Of the 848 that completed or were terminated, 330 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
314 of 1,131 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 7 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
70 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04442022Phase 3Karyopharm Therapeutics IncA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | 2026-12 |
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT04799275Phase 3National Cancer Institute (NCI)Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | 2027-03-01 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
Add all 70 to your calendar (.ics) → With an account.
Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have relapsed or refractory non-Hodgkin's lymphoma (NHL). The study looked at anti-tumor activity in participants who received alisertib.
The study enrolled 48 patients. Participants were categorized as per disease subtypes into five subtypes: Large B-Cell lymphoma, mantle cell lymphoma, transformed follicular lymphoma, Burkitts lymphoma and aggressive T-Cell lymphoma (Note: There were no participants enrolled with Precursor B-lymphoblastic Leukemia/Lymphoma). Participants received:
All participants took alisertib capsules approximately every 12 hours each day for 7 days followed by a 14-day rest period in a 21-days cycle. MLN8237 was supplied in capsules of 5 or 25 mg strength.
This multi-center trial was conducted in United States. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. If the participant would derive benefit from continued alisertib treatment beyond 24 months, the Sponsor was consulted for approval of further treatment. Participants made multiple visits to the clinic, with imaging assessments every 12 weeks. Participants discontinuing treatment prior to disease progression continue with clinic visits, chemistry and hematology lab testing, and tumor assessments every 12 weeks up to 12 months after last dose of study drug for follow-up assessments.
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
Participant must have histological or cytological diagnosis of a hematological of the following types that has or was refractory to prior therapy:
Exclusion criteria include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
Drug: Alisertib
Alisertib capsules
Also known as: MLN8237
Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria)
Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites (as specified in the Cheson 2007, IWG response criteria).
Time frame: Baseline and every 2 cycles up to Month 12 (approximately 16 cycles), from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months from last dose (Up to 4 years)
Time to Progression (TTP)
Time to progression (TTP) is defined as the time in days from the date of first study drug administration to the date of first documentation of Progressive Disease (PD) according to IWG criteria (Cheson 2007). PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Progression Free Survival (PFS)
PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death.
Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Duration of Response (DOR)
DOR is defined as the time from the date of first documentation of a CR, or partial response (PR) to the date of first documentation of PD according to IWG criteria. CR definition includes the complete disappearance of all evidence of disease, the definition of PR includes at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir, as described in the IWG response criteria (Cheson 2007).
Time frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years)
Number of Participants With Treatment-Emergent Adverse Events
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and includes all-causality (ie, treatment-related and not treatment-related as assessed by the investigator).
Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events
Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)
Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events
Abnormal laboratory values for chemistry or hematology tests that were assessed by the investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V4). A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of study drug to 30 days after last dose (Up to 25 months)
Participants took part in the study at 12 investigative sites in the United States from 10 February 2009 to last participant off study 13 February 2013, with a data cut-off on 04 January 2011 to report the primary endpoint.
| Milestone | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Started | 22 | 13 | 5 | 1 | 7 |
| Completed | 14 | 7 | 1 | 0 | 2 |
| Not completed | 8 | 6 | 4 | 1 | 5 |
| Withdrew: Adverse event | 6 | 3 | 1 | 1 | 2 |
| Withdrew: Withdrawal by patient | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 3 | 2 | 0 | 3 |
Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites (as specified in the Cheson 2007, IWG response criteria).
| percentage of participants | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) | 25 | 23 | 40 | 100 | 50 |
Time to progression (TTP) is defined as the time in days from the date of first study drug administration to the date of first documentation of Progressive Disease (PD) according to IWG criteria (Cheson 2007). PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir.
| days | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Time to Progression (TTP) | 84.0 (48.0 to 430.0) | 139.0 (48.0 to 809.0) | NA (NA to NA) | NA (NA to NA) | 237.0 (46.0 to 631.0) |
PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death.
| days | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 84.0 (48.0 to 364.0) | 139.0 (48.0 to 809.0) | NA (NA to NA) | NA (NA to NA) | 237.0 (46.0 to 631.0) |
DOR is defined as the time from the date of first documentation of a CR, or partial response (PR) to the date of first documentation of PD according to IWG criteria. CR definition includes the complete disappearance of all evidence of disease, the definition of PR includes at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, and PD is defined as any new lesion or increase by \>50% of previously involved sites from nadir, as described in the IWG response criteria (Cheson 2007).
| days | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Duration of Response (DOR) | 454.0 (182.0 to 565.0) | 646.0 (243.0 to 646.0) | NA (NA to NA) | NA (NA to NA) | 596.0 (202.0 to 596.0) |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and includes all-causality (ie, treatment-related and not treatment-related as assessed by the investigator).
| participants | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 22 | 13 | 5 | 1 | 7 |
Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Pyrexia | 7 | 0 | 0 | 0 | 2 |
| Hypotension | 6 | 1 | 1 | 0 | 1 |
| Weight decreased | 2 | 1 | 0 | 0 | 1 |
| Tachycardia | 1 | 0 | 0 | 0 | 2 |
| Hypertension | 1 | 0 | 0 | 0 | 0 |
| Bradycardia | 1 | 0 | 0 | 0 | 0 |
| Cardiac flutter | 1 | 0 | 0 | 0 | 0 |
Abnormal laboratory values for chemistry or hematology tests that were assessed by the investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V4). A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Thrombocytopenia | 11 | 5 | 3 | 1 | 5 |
| Alanine aminotransferase increased | 6 | 0 | 0 | 0 | 1 |
| Aspartate aminotransferase increased | 6 | 0 | 0 | 0 | 1 |
| Blood alkaline phosphatase increased | 6 | 0 | 0 | 0 | 1 |
| Hypokalaemia | 3 | 0 | 1 | 0 | 1 |
| Blood lactate dehydrogenase increased | 3 | 0 | 0 | 0 | 1 |
| Blood creatinine increased | 0 | 0 | 0 | 0 | 2 |
| Blood potassium decreased | 1 | 0 | 0 | 0 | 1 |
| Lymphopenia | 1 | 0 | 0 | 0 | 1 |
| Blood urea increased | 1 | 0 | 0 | 0 | 0 |
| Hypercalcaemia | 0 | 0 | 0 | 0 | 1 |
| Hypernatraemia | 0 | 0 | 0 | 0 | 1 |
| Hypophosphataemia | 0 | 0 | 0 | 0 | 1 |
| Mean cell volume increased | 0 | 0 | 0 | 0 | 1 |
| Urine colour abnormal | 0 | 1 | 0 | 0 | 0 |
| Neutropenia | 13 | 9 | 3 | 1 | 4 |
Collected over First dose of study drug to 30 days after last dose (Up to 25 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alisertib 50 mg BID Starting Dose (DLBL) | — | 16/22 (72.7%) | 22/22 (100%) |
| Alisertib 50 mg BID Starting Dose (MCL) | — | 4/13 (30.8%) | 13/13 (100%) |
| Alisertib 50 mg BID Starting Dose (TFL) | — | 5/5 (100%) | 5/5 (100%) |
| Alisertib 50 mg BID Starting Dose (BL) | — | 0/1 (0%) | 1/1 (100%) |
| Alisertib 50 mg BID Starting Dose (ATL) | — | 4/7 (57.1%) | 7/7 (100%) |
| Event | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 6/22 | 0/13 | 0/5 | 0/1 | 1/7 |
| NeutropeniaBlood and lymphatic system disorders | 3/22 | 2/13 | 1/5 | 0/1 | 1/7 |
| PneumoniaInfections and infestations | 3/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| CellulitisInfections and infestations | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| OsteomyelitisInfections and infestations | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| Oropharyngeal candidiasisInfections and infestations | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| Escherichia bacteraemiaInfections and infestations | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| Hallucination, visualPsychiatric disorders | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/22 | 0/13 | 1/5 | 0/1 | 0/7 |
| Event | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) |
|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 16/22 | 9/13 | 4/5 | 1/1 | 4/7 |
| AnaemiaBlood and lymphatic system disorders | 15/22 | 7/13 | 3/5 | 1/1 | 5/7 |
| LeukopeniaBlood and lymphatic system disorders | 13/22 | 8/13 | 3/5 | 1/1 | 4/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/22 | 5/13 | 3/5 | 1/1 | 5/7 |
| DiarrhoeaGastrointestinal disorders | 14/22 | 8/13 | 3/5 | 1/1 | 3/7 |
| StomatitisGastrointestinal disorders | 7/22 | 2/13 | 2/5 | 1/1 | 3/7 |
| AlopeciaSkin and subcutaneous tissue disorders | 9/22 | 8/13 | 4/5 | 1/1 | 1/7 |
| Rash erythematousSkin and subcutaneous tissue disorders | 0/22 | 0/13 | 0/5 | 1/1 | 0/7 |
| SomnolenceNervous system disorders | 9/22 | 4/13 | 2/5 | 1/1 | 5/7 |
| Decreased appetiteMetabolism and nutrition disorders | 7/22 | 2/13 | 0/5 | 1/1 | 3/7 |
Safety population was defined as all participants who received any amount of alisertib.
| Age, Continuous(years) | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) | Total |
|---|---|---|---|---|---|---|
| Mean | 66.8 ± 11.11 | 67.2 ± 6.71 | 65.2 ± 9.96 | 76.0 ± NA | 54.4 ± 16.90 | 65.1 ± 11.56 |
| Sex: Female, Male(Participants) | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) | Total |
|---|---|---|---|---|---|---|
| Female | 9 | 1 | 3 | 0 | 0 | 13 |
| Male | 13 | 12 | 2 | 1 | 7 | 35 |
| Race/Ethnicity, Customized(participants) | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) | Total |
|---|---|---|---|---|---|---|
| White | 21 | 13 | 5 | 1 | 7 | 47 |
| Other | 1 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 1 | 3 |
| Not Hispanic or Latino | 21 | 13 | 4 | 1 | 6 | 45 |
| Weight(kg) | Alisertib 50 mg BID Starting Dose (DLBL) | Alisertib 50 mg BID Starting Dose (MCL) | Alisertib 50 mg BID Starting Dose (TFL) | Alisertib 50 mg BID Starting Dose (BL) | Alisertib 50 mg BID Starting Dose (ATL) | Total |
|---|---|---|---|---|---|---|
| Mean | 88.85 ± 27.022 | 96.18 ± 25.139 | 89.06 ± 29.724 | 72.58 ± NA | 84.45 ± 14.494 | 89.88 ± 24.737 |
Ran from Feb 2009 to primary completion in Jan 2011, 22 months.
Results were first posted in Mar 2018, 7 years 2 months after primary completion. A results delay was requested in Jun 2012.
Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 22 months is below that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237
Lymphoma, Large B-Cell, Diffuse →
Millennium Pharmaceuticals, Inc. →